Proteomics Completes $1.44 million Placement and Offers SPP

2nd December 2016, ASX Announcement

Medtech company Proteomics International Laboratories Ltd (PILL, ASX: PIQ) is pleased to announce it has completed the first phase of a targeted capital raising by placement of 6m shares at $0.24 to raise $1.44m (the “Placement”).

• Oversubscribed Placement raised $1.44 million with support from existing and new sophisticated investors
• Share Purchase Plan to raise a further $480,000
• Funds to be used to accelerate commercialisation of breakthrough test, PromarkerD, and the rollout of new analytical testing services for the fast-growing clinical trials market
• Directors to participate in the SPP

The Placement received strong support from existing and new sophisticated investors and was significantly over-subscribed. The Placement was priced at $0.24 per share, a discount of 12.7% to the last sale price and the 20 day VWAP, and includes one for four attaching options. PILL also announces a Share Purchase Plan (SPP) to existing shareholders to raise $480,000 at $0.24 per share. K S Capital Pty Ltd acted as Lead Manager to the Placement.

To view the full announcement, please click on the button below.